Antivenom surveillance: An audit of antivenom stock within South Australia

Abstract

AbstractObjectivesAntivenoms are important emergency medications to be held within Australia, particularly in regional and remote locations. We audited current antivenom holdings in hospitals and health services across South Australia (SA) and compared to recommendations in the ‘Snakebite and Spiderbite Management Guidelines’ from the State's Toxinology service. The process also assessed the feasibility of ‘real‐time’ remote stock monitoring.MethodsFifty‐three sites listed in the guideline were recommended to hold antivenom, though only 49 are currently operational. Interrogation of antivenom stock for 29 sites was possible using electronic reports generated from the State Pharmacy database. The 20 remaining centres had their stock levels confirmed by calling the centres directly. Data obtained were then compared to recommended levels of antivenom holdings in the guideline with discrepancies and associated costs documented. A separate report verification process was used to determine ‘real‐time’ accuracy of the electronic reports.ResultsThirty‐seven sites (75%) held more than the recommended number of antivenom vials, totalling 129 vials in excess with an approximate total cost of $110 000. Twelve sites (24%) held inadequate stock to deliver a treatment dose for 19 envenoming events. The report verification revealed variances in the electronic reports.ConclusionsThis audit has demonstrated a significant disparity between recommended and actual antivenom holdings across most sites in SA and has also revealed that ‘real‐time’ remote monitoring of state antivenom holdings is not currently feasible. Correction of stock levels to that recommended may result in financial benefit for State Health while also addressing inequity in regional and remote healthcare provision.